New drug offers hope of cure for hormone-driven high blood pressure

image via Medical Xpress - medical research advances and health news

July 14, 2025, 3:27 PM

• •Baxdrostat, an aldosterone synthase inhibitor, led to significant blood pressure reduction.
• •The drug normalized potassium levels and suppressed aldosterone.
• •Larger trials are underway to confirm safety and effectiveness.
• •Regulatory approval is anticipated within two to three years.

A team of researchers at Queen Mary University of London discovered that Baxdrostat, an aldosterone synthase inhibitor, significantly reduced blood pressure in patients with primary aldosteronism, a condition often under-diagnosed. The SPARK Phase 2a clinical trial revealed an average fall in blood pressure of 25 mmHg, two to three times the reduction seen with typical antihypertensive drugs. The drug also normalized potassium levels and suppressed aldosterone levels. Larger clinical trials are planned, with the anticipation of regulatory approval within the next few years.

Read original article